Abstract:The lysosome is a membrane-enclosed organelle that is an essential part of the cell's digestive system. This organelle contains over 60 types of hydrolases that can break down biological polymers such as proteins, carbohydrates, lipids, and nucleic acids. These enzymes require an acidic pH for optimal function, which is achieved by using ATP hydrolysis to pump protons against their electrochemical gradient into the lysosome by the vacuolar H+ ATPase (V-ATPase). The biogenesis of lysosomes is known to be controlled by the coordination of the regulatory gene network and the lysosomal expression, which is governed by the nuclear translocation of transcription factor EB (TFEB). Lysosomes are an essential component of the inner membrane system and participate in numerous cell biological processes, such as macromolecular degradation, antigen presentation, intracellular pathogen destruction, plasma membrane repair, exosome release, cell adhesion/migration, and apoptosis. The primary function of lysosomes is to digest extracellular material that has been internalized by endocytosis and intracellular components that have been sequestered by autophagy. They recycle the unwanted cellular material as energy, providing a nutrient source for maintaining cellular homeostasis. Lysosomal activity affects the tumor microenvironment, making the tumor cells use energy more efficiently, and it is known to be increased compared to neighboring normal tissues. However, recent studies have shown that increased lysosomal activity can lead to downregulating Receptor tyrosine kinase (RTK) activity in cancer cells. RTK activity frequently occurs with mutations in EGFR in various human cancers. Thus, EGFR is currently a target for several cancer therapies. Recently, studies on EGFR-mediated tumors through lysosome regulation have been continuously conducted. According to our previous study, it has been found that lysosome inactivation suppresses the degradation of RKT, such as EGFR, and increases the expression of EGFR.EGFR is expressed in various human tumors, including gliomas and carcinomas of the lung, colon, head and neck, pancreas, breast, ovary, and kidney. Mutations, gene amplification, and protein overexpression of various pathway elements contribute to carcinogenesis and impact prognosis. Alterations within the EGFR signaling cascade, such as gene mutations, gene amplification, and protein overexpression, have been shown to contribute to colorectal carcinogenesis.[4]In this study, we will down-regulate the expression of EGFR by activating the lysosome in DLD-1, a colorectal cancer cell line. Lysosome was activated by overexpression of V-ATPase using the lentiviral system. In vitro experiments confirmed that the degradation of EGFR was actively performed in the lysosome-activated experimental group. It inhibited cancer cells' proliferation, survival, and differentiation. Targeting lysosomes may be a new approach to overcoming EGFR-mediated cancers. Citation Format: Dohyang Kim, Anlin Zhu, Jaewoo Hong. Treatment of EGFR-mediated tumors via lysosome activity regulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB046.

Targeted Reduction of the EGFR Protein, but Not Inhibition of Its Kinase Activity, Induces Mitophagy and Death of Cancer Cells Through Activation of Mtorc2 and Akt.

Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.

Targeting EGFR‐mediated Autophagy As a Potential Strategy for Cancer Therapy

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

EGFR-mediated Autophagy in Tumourigenesis and Therapeutic Resistance

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Abstract LB046: Treatment of EGFR-mediated tumors via lysosome activity regulation

Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death Upon Oncogene Inactivation in EGFR Addicted Cancers.

KEAP1-NRF2 pathway as a novel therapeutic target for EGFR-mutant non-small cell lung cancer

ERK5 Inhibition Induces Autophagy-Mediated Cancer Cell Death by Activating ER Stress

Abstract 2752: EGFR Tyrosine Kinase Inhibitor Limits Tumor Relapse Through Enhancing Anti-Tumor T Cell Responses

Mitochondrially Localized EGFR is Subjected to Autophagic Regulation and Implicated in Cell Survival.

Targeting Microtubules Sensitizes Drug Resistant Lung Cancer Cells to Lysosomal Pathway Inhibitors.

C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non–Small Cell Lung Cancer

Abstract 4832: Regulatory Role of EF-2 Kinase in Crosstalk Between Autophagy and Apoptosis and Its Impact on the Activity of a Novel AKT Inhibitor, MK-2206, Against Human Glioma Cells

Abstract 3870: TNF-MK2 signaling drives protective autophagy following MAPK pathway inhibition in pancreatic cancer

Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia